DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06564753

CompletedPhase 2

Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition

Asset

NA-931

Oral · GLP-1 / GIP / glucagon triple

Listed sites

5

Recruiting sites

—

Enrollment

126

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06564753
Org study IDNA-931-100

Timeline

Milestones

Study start2024-07-19actual
Study first posted2024-08-21actual
Primary completion2025-02-27actual
Study completion2025-04-18actual
Last update posted2025-05-23actual

Assets

Investigational agents

NA-931

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Age ≥18 years of age at the time of signing the informed consent

2. Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI <50 kg/m2

Exclusion criteria

1. History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation

2. Self-reported body weight change of 5% or more within 3 months of screening

3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)

4. Current or past diagnosis of chronic pancreatitis

5. Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)

6. Any Glucagon-Like Peptide 1 (GLP-1) receptor agonist or GLP-1/ Glucose-dependent Insulinotropic Polypeptide (GIP) dual agonist within 6 months of Screening

7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Safety / tolerability / PK
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

Percent (relative) change from baseline to Week 13 in body weight

Time frame:13 weeks

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13

Time frame:13 weeks

threshold achievement, improvement

components≥5% weight-loss responders, ≥10% weight-loss responders

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Incidence of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse event (TESAEs), adverse events of special interest (AESI)

Time frame:13 weeks

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.